New Drug Causes 20 Percent Weight Loss in Early Amgen Results
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month, compared with once a week for other obesity drugs like Wegovy and Zepbound that are already on the market.
Key TakeawaysA Phase 2 study of Amgen's experimental weight-loss treatment didn't meet expectations of analysts.Concerns were ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
STORY: Shares of Amgen on Tuesday were on track for their biggest percentage fall in more than two decades after the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback